≡

Breast Cancer Susceptibility Protein 2 (BRCA2)

[Edit]

BRCA2; BRCC2; FACD; FAD; FAD1; FANCD; FANCD1; Breast Cancer 2,Early Onset; Breast Cancer Type 2 Susceptibility Protein; Fanconi anemia group D1 protein

Breast Cancer Susceptibility Protein 2 (BRCA2)
CCC B364
HGNC 1101
MGI 109337
PubMed 8589730
RGD 2219
UniProt P51587
Wiki BRCA2

BRCA2 is a protein belongs to the tumor suppressor gene family and the protein encoded by this gene is involved in the repair of chromosomal damage with an important role in the error-free repair of DNA double strand breaks. The BRCA2 gene is located on the long (q) arm of chromosome 13 at position 12.3 (13q12.3), from base pair 31,787,616 to base pair 31,871,804.

The BRCA2 protein binds to and regulates the protein produced by the RAD51 gene to fix breaks in DNA.  These breaks can be caused by natural and medical radiation or other environmental exposures, but also occur when chromosomes exchange genetic material during a special type of cell division that creates sperm and eggs (meiosis).

Organism species: Homo sapiens (Human)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins RPB364Hu01 Recombinant Breast Cancer Susceptibility Protein 2 (BRCA2) Positive Control; Immunogen; SDS-PAGE; WB.
Antibodies PAB364Hu01 Polyclonal Antibody to Breast Cancer Susceptibility Protein 2 (BRCA2) WB
MAB364Hu22 Monoclonal Antibody to Breast Cancer Susceptibility Protein 2 (BRCA2) WB; IHC; ICC; IP.
Assay Kits SEB364Hu ELISA Kit for Breast Cancer Susceptibility Protein 2 (BRCA2) Enzyme-linked immunosorbent assay for Antigen Detection.

Organism species: Mus musculus (Mouse)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins RPB364Mu01 Recombinant Breast Cancer Susceptibility Protein 2 (BRCA2) Positive Control; Immunogen; SDS-PAGE; WB.
RPB364Mu02 Recombinant Breast Cancer Susceptibility Protein 2 (BRCA2) Positive Control; Immunogen; SDS-PAGE; WB.
Antibodies PAB364Mu01 Polyclonal Antibody to Breast Cancer Susceptibility Protein 2 (BRCA2) WB; IHC; ICC; IP.
PAB364Mu02 Polyclonal Antibody to Breast Cancer Susceptibility Protein 2 (BRCA2) WB; IHC; ICC; IP.
Assay Kits SEB364Mu ELISA Kit for Breast Cancer Susceptibility Protein 2 (BRCA2) Enzyme-linked immunosorbent assay for Antigen Detection.

Organism species: Rattus norvegicus (Rat)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins RPB364Ra01 Recombinant Breast Cancer Susceptibility Protein 2 (BRCA2) Positive Control; Immunogen; SDS-PAGE; WB.
Antibodies PAB364Ra01 Polyclonal Antibody to Breast Cancer Susceptibility Protein 2 (BRCA2) WB; IHC; ICC; IP.
Assay Kits n/a CLIA Kit for Breast Cancer Susceptibility Protein 2 (BRCA2) CLIA Kit Customized Service Offer
n/a ELISA Kit for Breast Cancer Susceptibility Protein 2 (BRCA2) ELISA Kit Customized Service Offer
  1. "Identification of the breast cancer susceptibility gene BRCA2." Nature 378:789-792(1995) [PubMed] [Europe PMC] [Abstract]
  2. "The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds." Nat. Genet. 12:333-337(1996) [PubMed] [Europe PMC] [Abstract]
  3. "The DNA sequence and analysis of human chromosome 13." Nature 428:522-528(2004) [PubMed] [Europe PMC] [Abstract]
  4. "Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients."Nat. Genet. 16:17-18(1997) [PubMed] [Europe PMC] [Abstract]
  5. "Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways."Hum. Mol. Genet. 13:1241-1248(2004) [PubMed] [Europe PMC] [Abstract]
  6. "Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin."Mol. Cell. Biol. 24:5850-5862(2004) [PubMed] [Europe PMC] [Abstract]
  7. "BRCA2 is ubiquitinated in vivo and interacts with USP11, a deubiquitinating enzyme that exhibits prosurvival function in the cellular response to DNA damage."Mol. Cell. Biol. 24:7444-7455(2004) [PubMed] [Europe PMC] [Abstract]
  8. "Biallelic BRCA2 mutations are associated with multiple malignancies in childhood including familial Wilms tumour."J. Med. Genet. 42:147-151(2005) [PubMed] [Europe PMC] [Abstract]
  9. "FANCD2 functions independently of BRCA2 and RAD51 associated homologous recombination in response to DNA damage."J. Biol. Chem. 280:14877-14883(2005) [PubMed] [Europe PMC] [Abstract]
  10. "CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair."Nature 434:598-604(2005) [PubMed] [Europe PMC] [Abstract]
  11. "WDRPUH, a novel WD-repeat-containing protein, is highly expressed in human hepatocellular carcinoma and involved in cell proliferation."Neoplasia 7:348-355(2005) [PubMed] [Europe PMC] [Abstract]
  12. "Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2."Mol. Cell 22:719-729(2006) [PubMed] [Europe PMC] [Abstract]
  13. "ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage."Science 316:1160-1166(2007) [PubMed] [Europe PMC] [Abstract]
  14. "FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3."Oncogene 27:3641-3652(2008) [PubMed] [Europe PMC] [Abstract]
  15. "The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage."Oncogene 27:3977-3985(2008) [PubMed] [Europe PMC] [Abstract]
  16. "PALB2 is an integral component of the BRCA complex required for homologous recombination repair."Proc. Natl. Acad. Sci. U.S.A. 106:7155-7160(2009) [PubMed] [Europe PMC] [Abstract]
  17. "Human BRCA2 protein promotes RAD51 filament formation on RPA-covered single-stranded DNA."Nat. Struct. Mol. Biol. 17:1260-1262(2010) [PubMed] [Europe PMC] [Abstract]
  18. "The breast cancer tumor suppressor BRCA2 promotes the specific targeting of RAD51 to single-stranded DNA."Nat. Struct. Mol. Biol. 17:1263-1265(2010) [PubMed] [Europe PMC] [Abstract]
  19. "Purified human BRCA2 stimulates RAD51-mediated recombination."Nature 467:678-683(2010) [PubMed] [Europe PMC] [Abstract]
  20. "BRCA2 and nucleophosmin coregulate centrosome amplification and form a complex with the Rho effector kinase ROCK2."Cancer Res. 71:68-77(2011) [PubMed] [Europe PMC] [Abstract]
  21. "Homologous recombination proteins are associated with centrosomes and are required for mitotic stability."Exp. Cell Res. 317:1203-1213(2011) [PubMed] [Europe PMC] [Abstract]
  22. "Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair."Oncogene 33:4803-4812(2014) [PubMed] [Europe PMC] [Abstract]
  23. "Breast cancer proteins PALB2 and BRCA2 stimulate polymerase eta in recombination-associated DNA synthesis at blocked replication forks."Cell Rep. 6:553-564(2014) [PubMed] [Europe PMC] [Abstract]
  24. "BRCA2 prevents R-loop accumulation and associates with TREX-2 mRNA export factor PCID2."Nature 511:362-365(2014) [PubMed] [Europe PMC] [Abstract]
  25. "Insights into DNA recombination from the structure of a RAD51-BRCA2 complex."Nature 420:287-293(2002) [PubMed] [Europe PMC] [Abstract]
  26. "Structural basis for recruitment of BRCA2 by PALB2."EMBO Rep. 10:990-996(2009) [PubMed] [Europe PMC] [Abstract]
  27. "Mutations of the BRCA2 gene in ovarian carcinomas."Cancer Res. 56:2738-2741(1996) [PubMed] [Europe PMC] [Abstract]
  28. "BRCA2 germline mutations in male breast cancer cases and breast cancer families."Nat. Genet. 13:123-125(1996) [PubMed] [Europe PMC] [Abstract]
  29. "BRCA2 mutations in primary breast and ovarian cancers."Nat. Genet. 13:238-240(1996) [PubMed] [Europe PMC] [Abstract]
  30. "Low incidence of BRCA2 mutations in breast carcinoma and other cancers."Nat. Genet. 13:241-244(1996) [PubMed] [Europe PMC] [Abstract]
  31. "Mutation analysis in the BRCA2 gene in primary breast cancers."Nat. Genet. 13:245-247(1996) [PubMed] [Europe PMC] [Abstract]
  32. "A low proportion of BRCA2 mutations in Finnish breast cancer families."Am. J. Hum. Genet. 60:1050-1058(1997) [PubMed] [Europe PMC] [Abstract]
  33. "High throughput fluorescence-based conformation-sensitive gel electrophoresis (F-CSGE) identifies six unique BRCA2 mutations and an overall low incidence of BRCA2 mutations in high-risk BRCA1-negative breast cancer families."Hum. Genet. 102:549-556(1998) [PubMed] [Europe PMC] [Abstract]
  34. "High proportion of missense mutations of the BRCA1 and BRCA2 genes in Japanese breast cancer families." J. Hum. Genet. 43:42-48(1998) [PubMed] [Europe PMC] [Abstract]
  35. "The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes."Am. J. Hum. Genet. 65:1021-1029(1999) [PubMed] [Europe PMC] [Abstract]
  36. "Molecular characterization of germline mutations in the BRCA1 and BRCA2 genes from breast cancer families in Taiwan."Hum. Genet. 104:201-204(1999) [PubMed] [Europe PMC] [Abstract]
  37. "Global sequence diversity of BRCA2: analysis of 71 breast cancer families and 95 control individuals of worldwide populations." Hum. Mol. Genet. 8:413-423(1999) [PubMed] [Europe PMC] [Abstract]
  38. "Germline brca2 sequence variants in patients with ocular melanoma."Int. J. Cancer 82:325-328(1999) [PubMed] [Europe PMC] [Abstract]
  39. "A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability."Nat. Genet. 26:362-364(2000) [PubMed] [Europe PMC] [Abstract]
  40. "BRCA2 germline mutations among early onset breast cancer patients unselected for family history of the disease."J. Med. Genet. 37:E17-E17(2000) [PubMed] [Europe PMC] [Abstract]
  41. "BRCA2 germline mutations in male breast cancer patients in the Polish population."Hum. Mutat. 17:73-73(2001) [PubMed] [Europe PMC] [Abstract]
  42. "An improved high throughput heteroduplex mutation detection system for screening BRCA2 mutations-fluorescent mutation detection (F-MD)."Hum. Mutat. 17:220-232(2001) [PubMed] [Europe PMC] [Abstract]
  43. "BRCA2 T2722R is a deleterious allele that causes exon skipping."Am. J. Hum. Genet. 71:625-631(2002) [PubMed] [Europe PMC] [Abstract]
  44. ErratumAm. J. Hum. Genet. 73:1477-1477(2002)
  45. "BRCA2 gene mutations in families with aggregations of breast and stomach cancers."Br. J. Cancer 87:888-891(2002) [PubMed] [Europe PMC] [Abstract]
  46. "Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%."Cancer Res. 62:3789-3793(2002) [PubMed] [Europe PMC] [Abstract]
  47. "Infrequent mutation in the BRCA2 gene in esophageal squamous cell carcinoma."Clin. Cancer Res. 8:1121-1126(2002) [PubMed] [Europe PMC] [Abstract]
  48. "Characterization of common BRCA1 and BRCA2 variants."Genet. Test. 6:119-121(2002) [PubMed] [Europe PMC] [Abstract]
  49. "BRCA1 and BRCA2 in Indian breast cancer patients."Hum. Mutat. 20:473-474(2002) [PubMed] [Europe PMC] [Abstract]
  50. "BRCA1 and BRCA2 sequence variants in Chinese breast cancer families."Hum. Mutat. 20:474-474(2002) [PubMed] [Europe PMC] [Abstract]
  51. "BRCA1 and BRCA2 mutation analysis of early-onset and familial breast cancer cases in Mexico."Hum. Mutat. 20:474-475(2002) [PubMed] [Europe PMC] [Abstract]
  52. "Somatic mutations in the BRCA2 gene and high frequency of allelic loss of BRCA2 in sporadic male breast cancer."Int. J. Cancer 98:943-945(2002) [PubMed] [Europe PMC] [Abstract]
  53. "Biallelic inactivation of BRCA2 in Fanconi anemia."Science 297:606-609(2002) [PubMed] [Europe PMC] [Abstract]
  54. "BRCA2 germline mutations in Cypriot patients with familial breast/ovarian cancer."Hum. Mutat. 21:171-171(2003) [PubMed] [Europe PMC] [Abstract]
  55. "Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families in Southern Germany."Hum. Mutat. 22:259-259(2003) [PubMed] [Europe PMC] [Abstract]
  56. "Evaluation of the diagnostic accuracy of the stop codon (SC) assay for identifying protein-truncating mutations in the BRCA1and BRCA2genes in familial breast cancer."J. Hum. Genet. 48:130-137(2003) [PubMed] [Europe PMC] [Abstract]
  57. "BRCA2 germline mutations in familial pancreatic carcinoma."J. Natl. Cancer Inst. 95:214-221(2003) [PubMed] [Europe PMC] [Abstract]
  58. "Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood."Blood 103:2554-2559(2004) [PubMed] [Europe PMC] [Abstract]
  59. "BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families."Br. J. Cancer 90:1244-1251(2004) [PubMed] [Europe PMC] [Abstract]
  60. "Hereditary breast and ovarian cancer in Cyprus: identification of a founder BRCA2 mutation."Cancer Genet. Cytogenet. 151:152-156(2004) [PubMed] [Europe PMC] [Abstract]
  61. "One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden."Eur. J. Cancer 40:422-428(2004) [PubMed] [Europe PMC] [Abstract]
  62. "Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast and breast-ovarian cancer families."Hum. Mutat. 23:205-205(2004) [PubMed] [Europe PMC] [Abstract]
  63. "RNA analysis reveals splicing mutations and loss of expression defects in MLH1 and BRCA1."Hum. Mutat. 24:272-272(2004) [PubMed] [Europe PMC] [Abstract]
  64. "BRCA1 and BRCA2 germline mutations in Korean patients with sporadic breast cancer."Hum. Mutat. 24:350-350(2004) [PubMed] [Europe PMC] [Abstract]
  65. "Prevalence of BRCA2 mutations in a hospital based series of unselected breast cancer cases."J. Med. Genet. 42:E5-E5(2005) [PubMed] [Europe PMC] [Abstract]
  66. "A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes."Am. J. Hum. Genet. 81:873-883(2007) [PubMed] [Europe PMC] [Abstract]
  67. "Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2."J. Med. Genet. 44:1-9(2007) [PubMed] [Europe PMC] [Abstract]
  68. "Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity."Hum. Mutat. 31:E1484-E1505(2010) [PubMed] [Europe PMC] [Abstract]